Enzo Biochem, Inc. (EZB.F)
- Previous Close
0.3540 - Open
0.4240 - Bid 0.3600 x 120000
- Ask 0.4400 x 120000
- Day's Range
0.4240 - 0.4240 - 52 Week Range
0.0100 - 1.1300 - Volume
400 - Avg. Volume
135 - Market Cap (intraday)
27.154M - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date Jun 11, 2025 - Jun 16, 2025
- Forward Dividend & Yield 0.38 (107.17%)
- Ex-Dividend Date Nov 15, 2024
- 1y Target Est
--
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
www.enzo.comRecent News: EZB.F
View MorePerformance Overview: EZB.F
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EZB.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EZB.F
View MoreValuation Measures
Market Cap
22.67M
Enterprise Value
-10.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.71
Price/Book (mrq)
0.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-73.25%
Return on Assets (ttm)
-7.46%
Return on Equity (ttm)
-12.94%
Revenue (ttm)
29.09M
Net Income Avi to Common (ttm)
-7.6M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
40.3M
Total Debt/Equity (mrq)
6.73%
Levered Free Cash Flow (ttm)
-661.12k